|
1.
|
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 -  10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
|
2.
|
|
11 p, 4.4 MB |
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome
/
Salz, Lucia (RWTH Aachen University Medical School, Germany) ;
Seitz, Alexander (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Schäfer, Daniel (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Franzen, Julia (RWTH Aachen University Medical School, Germany) ;
Holzer, Tatjana (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bürger, Iris (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Hardt, Olaf (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wagner, Wolfgang (RWTH Aachen University Medical School, Germany)
Chimeric antigen receptor (CAR) T cells provide new perspectives for treatment of hematological malignancies. Manufacturing of these cellular products includes culture expansion procedures, which may affect cellular integrity and therapeutic outcome. [...]
2023 - 10.1038/s41375-023-01966-1
Leukemia, Vol. 37 Núm. 9 (july 2023) , p. 1868-1878
|
|
|
3.
|
|
18 p, 3.7 MB |
The KMT2A recombinome of acute leukemias in 2023
/
Meyer, Claus (DCAL/Institute of Pharm. Biology. Goethe-University(Alemanya)) ;
Larghero, Patrizia (DCAL/Institute of Pharm. Biology. Goethe-University (Alemanya)) ;
Lopes, BA. (DCAL/Institute of Pharm. Biology. Goethe-University (Alemanya)) ;
Burmeister, Thomas (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany) ;
Gröger, Daniela (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin (Alemanya)) ;
Sutton, Rosemary (Molecular Diagnostics. Children's Cancer Institute. Lowy Cancer Research Centre. UNSW (Sidney, Austràlia)) ;
Venn, Nicola C. (Molecular Diagnostics. Children's Cancer Institute. Lowy Cancer Research Centre. UNSW (Sidney, Austràlia)) ;
Cazzaniga, Giovanni (University of Milano-Bicocca/Fondazione Tettamanti (Itàlia)) ;
Corral Abascal, Lilia (University of Milano-Bicocca/Fondazione Tettamanti (Itàlia)) ;
Tsaur, Grigory А. (Research Institute of Medical Cell Technologies (Ekaterinburg, Rússia)) ;
Fechina, Larisa G. (Research Institute of Medical Cell Technologies (Ekaterinburg, Rússia)) ;
Emerenciano, Mariana (Instituto Nacional de Câncer (INCA)(Rio de Janeiro, Brasil)) ;
Pombo-de-Oliveira, Maria S. (Instituto Nacional de Câncer (INCA)(Rio de Janeiro, Brasil)) ;
Lund-Aho, Tiina (Laboratory of Clinical Genetics, Fimlab Laboratories (Tampere, Finlàndia)) ;
Lundán, Tuija (University of Turku and Turku University Hospital (Turku, Finlàndia)) ;
Montonen, M. (University of Turku and Turku University Hospital (Turku, Finlàndia)) ;
Juvonen, Vesa (University of Turku and Turku University Hospital (Turku, Finlàndia)) ;
Zuna, Jan (Charles University and University Hospital Motol (Praga, República Txeca)) ;
Trka, Jan M. (Charles University and University Hospital Motol (Praga, República Txeca)) ;
Ballerini, Paola (Pierre et Marie Curie University (París, França)) ;
Lapillonne, Hélène (Pierre et Marie Curie University (París, França)) ;
Van der Velden, Vincent (University Medical Center Rotterdam (Països Baixos)) ;
Sonneveld, Edwin (Princess Máxima Center for Pediatric Oncology (Utrecht, Països Baixos)) ;
Delabesse, Éric C. M. (Institut Universitaire du Cancer de Toulouse (França)) ;
Capela de Matos, Roberto (National Cancer Institute (INCA) (Rio de Janeiro, Brasil)) ;
Silva, Maria Luiza (National Cancer Institute (INCA) (Rio de Janeiro, Brasil)) ;
Bomken, Simon (Newcastle University, Newcastle upon Tyne (Regne Unit)) ;
Katsibardi, Katerina (National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital (Atenes, Grècia)) ;
Keernik, Maria (Tartu University Hospital (Tartu, Estònia)) ;
Grardel, Nathalie (Department of Hematology, CHU Lille (França)) ;
Mason, J. (Newcastle University and the Great North Children's West Midlands Regional Genetics Laboratory (Regne Unit)) ;
Price, Richard (Newcastle University and the Great North Children's West Midlands Regional Genetics Laboratory (Regne Unit)) ;
Kim, J. (DCAL/Institute of Pharm. Biology. Goethe-University (Alemanya)) ;
Eckert, Cornelia (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin (Alemanya)) ;
Lo Nigro, Luca (Centro di Riferimento Regionale di Ematologia ed Oncologia Pediatrica, Azienda Policlinico "G. Rodolico" (Catània, Itàlia)) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menendez Bujan, P. (Centro di Riferimento Regionale di Ematologia ed Oncologia Pediatrica, Azienda Policlinico "G. Rodolico" (Catània, Itàlia)) ;
Zur Stadt, Udo (University Medical Center Hamburg-Eppendorf (Hamburg, Alemanya)) ;
Gameiro, Paula (Instituto Português de Oncologia, Departament of Hematology (Lisboa, Portugal)) ;
Sedek, Łukasz (Medical University of Silesia (Zabrze, Polònia)) ;
Szczepanski, Tomasz (Medical University of Silesia (Zabrze, Polònia)) ;
Bidet, A. (Laboratoire d'Hématologie Biologique, CHU Bordeaux (França)) ;
Marcu, Victoria (Hematology Laboratory, Sheba Medical Center, Tel-Hashomer, Israel) ;
Shichrur, Keren (Schneider Children's Medical Center of Israel, Petah Tikva, Israel) ;
Izraeli, Shai (Tel Aviv University, Tel Aviv, Israel) ;
Madsen, Hans Ole (Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark) ;
Schäfer, Beat (University Children's Hospital Zurich (Zúric, Suïssa)) ;
Kubetzko, Susanne (University Children's Hospital Zurich (Zúric, Suïssa)) ;
Kim, Rathana (Université Paris Cité (França)) ;
Clappier, Emmanuelle (Université Paris Cité (França)) ;
Trautmann, Heiko (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Brüggemann, Monika (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Archer, Paul (Bristol Genetics Laboratory, North Bristol NHS Trust (Bristol, Regne Unit)) ;
Hancock, Jeremy P. (Bristol Genetics Laboratory, North Bristol NHS Trust (Bristol, Regne Unit)) ;
Alten, Julia (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Möricke, Anja (University Hospital Schleswig-Holstein (Kiel, Alemanya)) ;
Stanulla, Martin (Department of Pediatrics, MHH (Hanover, Alemanya)) ;
Lentes, Jana (Medical School Hannover (Alemanya)) ;
Bergmann, Anke K. (Medical School Hannover (Alemanya)) ;
Strehl, Sabine (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Köhrer, Stefan (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Nebral, Karin (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Dworzak, Michael Norbert (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Haas, Oskar A. (St. Anna Children's Cancer Research Institute (CCRI) (Vienna, Àustria)) ;
Arfeuille, Chloe (Hopital Robert Debré (París, França)) ;
Caye Eude, Aurélie (Hopital Robert Debré (París, França)) ;
Cavé, Hélène (Hopital Robert Debré (París, França)) ;
Marschalek, Rolf (Goethe-University (Alemanya))
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. [...]
2023 - 10.1038/s41375-023-01877-1
Leukemia, Vol. 37 Núm. 5 (may 2023) , p. 988-1005
|
|
|
4.
|
|
4 p, 1.4 MB |
Remodeling of the m6A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages
/
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Piñeyro, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Prieto, Carlos A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Barahona, Vanessa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martinez-Verbo, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Webster, Natalie A. (STORM Therapeutics Ltd, UK) ;
Andrews, Byron (STORM Therapeutics Ltd, UK) ;
Kol, Nitzan (Tel Aviv University, Israel) ;
Avrahami, Chen (Tel Aviv University, Israel) ;
Moshitch-Moshkovitz, Sharon (Tel Aviv University, Israel) ;
Rechavi, Gideon (Tel Aviv University, Israel) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
2022 - 10.1038/s41375-022-01621-1
Leukemia, Vol. 36 Núm. 8 (august 2022) , p. 2121-2124
|
|
|
5.
|
|
16 p, 1.0 MB |
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Dimopoulos, Meletios (National and Kapodistrian University) ;
Schjesvold, Fredrik (University of Oslo) ;
Beksac, Meral (Ankara Üniversitesi Tip Fakültes) ;
Facon, Thierry (Hôpital Claude Huriez CHU de Lille) ;
Dhanasiri, Sujith (Celgene International Sàrl. a Bristol-Myers Squibb Company (Suïssa)) ;
Guo, Shien (Evidera) ;
Mu, Yutian (Evidera) ;
Hong, Kevin (Bristol Myers Squibb) ;
Gentili, Christian (Bristol Myers Squibb) ;
Galli, Mónica (ASST Papa Giovanni XXIII) ;
Yagci, Munci (Gazi University) ;
Larocca, Alessandra (University of Torino) ;
Richardson, Paul (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf (Alemanya))
Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. [...]
2023 - 10.1016/j.clml.2023.10.009
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
6.
|
|
9 p, 1.0 MB |
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain : The CharisMMa Study
/
Ocio, Enrique M. (Instituto de Investigación Sanitaria Valdecilla (Cantàbria)) ;
Montes-Gaisán, Carmen (Instituto de Investigación Sanitaria Valdecilla (Cantàbria)) ;
Bustamante, Gabriel (Institut Català d'Oncologia) ;
Garzón, Sebastián (Hospital de Jerez) ;
González, Esther (Hospital Universitario de Cabueñes (Gijón)) ;
Pérez Persona, Ernesto (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Sirvent, Maialen (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Arguiñano, José M (Complejo Hospitalario Navarra) ;
González, Yolanda (Institut Català d'Oconologia) ;
Ríos-Tamayo, Rafael (Hospital Universitario Virgen de las Nieves (Granada)) ;
de Miguel, Dunia de (Hospital Universitario de Guadalajara) ;
Grande, Marta (Universidad de Alcalá) ;
Fernández, Alfonso (Takeda Farmacéutica España) ;
Naves, Andrea (Takeda Farmacéutica España) ;
Rosiñol, Laura (Universitat de Barcelona)
Introduction: Treatment of relapsed and/or refractory multiple myeloma (RRMM) should be established based on multiple factors, including previous treatment and the sociodemographic/clinical characteristics of the patients. [...]
2022 - 10.1016/j.clml.2021.10.001
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 4 (april 2022) , p. e241-e249
|
|
|
7.
|
|
9 p, 603.3 KB |
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study
/
Martin, Thomas G. (University of California San Francisco, USA) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ;
Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ;
Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
San-Miguel, Jesús F. (Clínica Universidad de Navarra) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K. (Emory University, Atlanta, GA) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ;
Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Bahlis, Nizar (University of Calgary, Canada) ;
Popat, Rakesh (University College London) ;
Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ;
Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ;
Pei, Lixia (Janssen Research & Development, Raritan, NJ) ;
Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ;
Fastenau, John (Janssen Research & Development, Raritan, NJ) ;
Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ;
van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
8.
|
|
9 p, 821.4 KB |
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma : Final Results of a Randomized Phase III Study
/
Kwak, Larry W. (Comprehensive Cancer Center, Duarte) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Seok Goo (The Catholic University of Korea, Seoul, South Korea) ;
Nakazawa, Hideyuki (Shinshu University School of Medicine, Nagano, Japan) ;
Suzumiya, Junji (Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan) ;
Tumyan, Gayane (Division of Hematology and Bone Marrow Transplantation, Blokhin Russian Cancer) ;
Kim, Jin Seok (Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea) ;
Menne, Tobias (Newcastle University, UK) ;
Mariz, José (Instituto Português de Oncología do Porto) ;
Ilyin, Nikolai (Ministry of Health of the Russian Federation) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland) ;
Lopez Martinez, Aurelio (Hospital Arnau de Vilanova (València)) ;
Samoilova, Olga (Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia) ;
Zhavrid, Edvard (N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Belarus) ;
Yañez Ruiz, Eduardo (Universidad de la Frontera, Temuco, Chile) ;
Trneny, Marek (Charles University, Czech Republic) ;
Popplewell, Leslie (Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA) ;
Ogura, Michinori (Kasugai Municipal Hospital, Aichi 486-8510, Japan.) ;
Kim, Wong Seog (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Lee, Sang Joon (Celltrion. Inc, South Korea) ;
Kim, Sung Hyun (Celltrion. Inc, South Korea) ;
Ahn, Keum Young (Celltrion. Inc, South Korea) ;
Buske, Christian (University Hospital of Ulm, Germany)
Introduction: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. [...]
2022 - 10.1016/j.clml.2021.08.005
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 2 (february 2022) , p. 89-97
|
|
|
9.
|
|
8 p, 2.0 MB |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
/
Bahlis, Nizar J (University of Calgary) ;
Corso, A. (Policlinico San Matteo Universita di Pavia) ;
Mugge, L.O. (Universitätsklinikum Jena Klinik für Innere Medizin II) ;
Shen, Z.X. (Shanghai Jiao Tong University) ;
Desjardins, P. (Hôpital Charles LeMoyne) ;
Stoppa, A.M. (Institut Paoli Calmettes) ;
Decaux, O. (CHRU Hôpital Sud Médecine Interne) ;
De Revel, T. (Hôpital d'Instruction des Armées PERCY) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Marit, G. (CHU de Bordeaux) ;
Nahi, H. (Karolinska Institutet (Suecia)) ;
Demuynck, H. (H. Hart Ziekenhuis Roeselare-Menen) ;
Huang, S.Y. (National Taiwan University Hospital (Taipei, Taiwan)) ;
Basu, S. (New Cross Hospital) ;
Guthrie, T.H. (21st Century Oncology) ;
Ervin-Haynes, A. (Celgene Corporation) ;
Marek, J. (Celgene Corporation) ;
Chen, G. (Celgene Corporation) ;
Facon, T. (CHRU Lille) ;
Universitat Autònoma de Barcelona
The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT. [...]
2017 - 10.1038/leu.2017.111
Leukemia, Vol. 31 Núm. 11 (january 2017) , p. 2435-2442
|
|
|
10.
|
|
9 p, 500.3 KB |
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
/
Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hillmen, Peter (St James Institute of Oncology) ;
O'Brien, S. (MD Anderson Cancer Center) ;
Barrientos, J.C. (Hofstra Northwell School of Medicine) ;
Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, S.E. (Stanford University) ;
Tam, Constantine S (Peter MacCallum Cancer Centre. St Vincent's Hospital) ;
Mulligan, S.P. (Royal North Shore Hospital) ;
Jaeger, U. (Medical University of Vienna) ;
Barr, P.M. (University of Rochester Cancer Center) ;
Furman, R.R. (New York Presbyterian Hospital) ;
Kipps, Thomas J (UCSD Moores Cancer Center) ;
Cymbalista, F. (Hôpital Avicenne) ;
Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ;
Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ;
Delgado, J. (Hospital Clínic i Provincial de Barcelona) ;
Montillo, M. (Niguarda Hospital) ;
DeVos, S. (David Geffen School of Medicine at UCLA) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Pagel, J.M. (Swedish Cancer Institute) ;
Munir, Talha (St James Institute of Oncology) ;
Burger, Jan A (MD Anderson Cancer Center) ;
Chung, D. (Pharmacyclics LLC. AbbVie Company) ;
Lin, J. (Pharmacyclics LLC. AbbVie Company) ;
Gau, L. (Pharmacyclics LLC. AbbVie Company) ;
Chang, B. (Pharmacyclics LLC. AbbVie Company) ;
Cole, G. (Pharmacyclics LLC. AbbVie Company) ;
Hsu, E. (Pharmacyclics LLC. AbbVie Company) ;
James, D.F. (Pharmacyclics LLC. AbbVie Company) ;
Byrd, J.C. (Ohio State University) ;
Universitat Autònoma de Barcelona
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. [...]
2018 - 10.1038/leu.2017.175
Leukemia, Vol. 32 Núm. 1 (january 2018) , p. 83-91
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
